The role of talactoferrin alfa in the treatment of non-small cell lung cancer

Expert Opinion on Biological Therapy

Volumn 10, Issue 9, 2010, Pages 1379-1386

  Kelly, Ronan J ^a   Giaccone, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Dendritic cell; Immunotherapy; Non small cell lung cancer; Talactoferrin alpha

Indexed keywords

CARBOPLATIN; INTERLEUKIN 18; LACTOFERRICIN; PACLITAXEL; PLACEBO; TALACTOFERRIN ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LACTOFERRIN; TALACTOFERRIN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; CANCER GROWTH; CANCER PREVENTION; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DENDRITIC CELL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FATIGUE; FLATULENCE; HUMAN; INTESTINE LYMPHATIC TISSUE; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; REVIEW; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT; ANIMAL; CLINICAL TRIAL (TOPIC); EVIDENCE BASED MEDICINE; IMMUNOLOGY; LUNG TUMOR; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; EVIDENCE-BASED MEDICINE; HUMANS; LACTOFERRIN; LUNG NEOPLASMS; TREATMENT OUTCOME;

EID: 77955520692     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2010.512914     Document Type: Review

References (32)

1. Anderson BF, Baker HM, Norris GE, et al. Structure of human lactoferrin: crystallographic structure analysis and refinement at 2.8A resolution. J Mol Biol 1989;209:711-734
2. Sun XL, Baker HM, Shewry SC, et al. Structure of recombinant human lactoferrin expressed in Aspergillus awamori. Acta Crystallogr D Biol Crystallogr 1999;55:403-407
3. Levay PF, Viljoen M. Lactoferrin: a general review. Haematologica 1995;80:252-267
4. Bellamy W, Takase M, Wakabayashi H, et al. Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J Appl Bacteriol 1992;73:472-479
5. Legrand D, Elass E, Carpentier M, Mazurier J. Interactions of lactoferrin with cells involved in immune function. Biochem Cell Biol 2006;84:282-290
6. Bezault J, Bhimani R, Wiprovnick J, Furmanski P. Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res 1994;54:2310-2312
7. Tsuda H, Sekine K, Fujita K, Ligo M. Cancer prevention by bovine lactoferrin and underlying mechanisms-a review of experimental and clinical studies. Biochem Cell Biol 2002;80:131-136
8. Gahr M, Speer CP, Damerau B, Sawatzki G. Influence of lactoferrin on the function of human polymorphonuclear leukocytes and monocytes. J Leukoc Biol 1991;49:427-433
9. Hayes TG, Falchook GF, Varadhachary GR, et al. Phase I trial of oral talactoferrin alfa in refractory solid tumors. Invest New Drugs 2006;24:233-240
10. Xiao Y, Monitto CL, Minhas KM, Sidransky D. Lactoferrin down-regulates G1 cyclin-dependent kinases during growth arrest of head and neck cancer cells. Clin Cancer Res 2004;10:8683-8686
11. Damiens E, El Yazidi I, Mazurier J, et al. Lactoferrin inhibits G1 cyclin-dependent kinases during growth arrest of human breast carcinoma cells. J Cell Biochem 1999;74:486-498
12. Togawa J, Nagase H, Tanaka K, et al. Lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. Am J Physiol Gastrointest Liver Physiol 2002;283:G187-95
13. Zucali JR, Broxmeyer HE, Levy D, Morse C. Lactoferrin decreases monocyte-induced fibroblast production of myeloid colony-stimulating activity by suppressing monocyte release of interleukin-1. Blood 1989;74:1531-1536
14. Wolf JS, Li G, Varadhachary A, et al. Oral lactoferrin results in T cell-dependent tumor inhibition of head and neck squamous cell carcinoma in vivo. Clin Cancer Res 2007;13:1601-1610
15. Guillen C, McInnes IB, Vaughan DM, et al. Enhanced Th1 response to Staphylococcus aureus infection in human lactoferrin-transgenic mice. J Immunol 2002;168:3950-3957
16. Kuhara T, Iigo M, Itoh T, et al. Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr Cancer 2000;38:192-199
17. Wang WP, Iigo M, Sato J, et al. Activation of intestinal mucosal immunity in tumor-bearing mice by lactoferrin. Jpn J Cancer Res 2000;91:1022-1027
18. Artym J, Zimecki M, Kruzel ML. Reconstitution of the cellular immune response by lactoferrin in cyclophosphamide-treated mice is correlated with renewal of T cell compartment. Immunobiology 2003;207:197-205
19. Masuda C, Wanibuchi H, Sekine K, et al. Chemopreventive effects of bovine lactoferrin on N-butyl-N-(4-hydroxybutyl) nitrosamine-induced rat bladder carcinogenesis. Jpn J Cancer Res 2000;91:582-588
20. Sekine K, Watanabe E, Nakamura J, et al. Inhibition of azoxymethane-initiated colon tumor by bovine lactoferrin administration in F344 rats. Jpn J Cancer Res 1997;88:523-526
21. Suzuki YA, Shin K, Lonnerdal B. Molecular cloning and functional expression of a human intestinal lactoferrin receptor. Biochemistry 2001;40:15771-15779
22. Suzuki YA, Lonnerdal B. Characterization of mammalian receptors for lactoferrin. Biochem Cell Biol 2002;80:75-80
23. Talukder MJ, Takeuchi T, Harada E. Characteristics of lactoferrin receptor in bovine intestine: higher binding activity to the epithelium overlying Peyers patches. J Vet Med A Physiol Pathol Clin Med 2003;50:123-131
24. Hu WL, Mazurier J, Montreuil J, Spik G. Isolation and partial characterization of a lactotransferrin receptor from mouse intestinal brush border. Biochemistry 1990;29:535-541
25. Varadhachary A, Wolf JS, Petrak K, et al. Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. Int J Cancer 2004;111:398-403
26. Ishii K, Takamura N, Shinohara M, et al. Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months. Hepatol Res 2003;25:226-233
27. Parikh PK, Wang Y, Ranade AA, et al. Oral talactoferrin extends survival in patients with refractory NSCLC in a randomized, placebo-controlled, phase 2 trial (Meeting Abstracts). J Clin Oncol 2007;25(18 Suppl):7540
28. Wang Y, Raghunadharao D, Raman G, et al. Adding oral talactoferrin to first-line NSCLC chemotherapy safely enhanced efficacy in a randomized trial (Meeting Abstracts). J Clin Oncol 2006;24(18 Suppl):7095
29. Hayes TG, Digumarti R, Engelmeyer J, et al. Effect of oral talactoferrin (TLF) on levels of cytokines involved in the Th1-mediated immune response in clinical studies (Meeting Abstracts). J Clin Oncol 2008;26(15 Suppl):3080
30. Jonasch E, Stadler WM, Bukowski RM, et al. Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer 2008;113:72-77
31. Osada T, Chong G, Tansik R, et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008;57:1115-1124
32. Srinivas S, Stadler WM, Bukowski R, et al. Talactoferrin alfa may prolong progression-free survival in advanced renal carcinoma patients (Meeting Abstracts). J Clin Oncol 2006;24(18 Suppl):4600